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ABSTRACT
Because of a lack of consistent research, antidepressant usage during pregnancy is
a confusing subject for consumers. Results from some studies imply that
antidepressant usage during pregnancy for the treatment of depression and other
mood disorders can have negative effects on a child. Conflicting evidence
indicates that the negative effects potentially caused by antidepressants are not as
intense as the effects of untreated depression during pregnancy. Current research
on antidepressant usage during pregnancy only examines general health measures
in infants and toddlers and does not examine effects on older children who are
able to be assessed for potential cognitive and mood influences of perinatal
antidepressants. This study investigated the effects of maternal antidepressant
usage on psychological development in children at 9-10 years of age and 11-12
years of age. The data showed that perinatal medication usage did not affect
children’s mental health in early adolescence. The use of antidepressants during
pregnancy is potentially safe for the fetus, the childbearing parent, and the child
during early adolescence.
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Introduction
In the United States, depression is second only to heart disease as a
leading cause of medical disability (Michaud 2001). Women are vulnerable to
mood instability at times of life-cycle related hormonal changes including
pregnancy, post-miscarriage, postpartum and perimenopause (Burt, et al., 2008).
There are neurobiological, genetic, and psychosocial factors that influence the
increased vulnerability for depression in women (Burt and Quezada, 2009). The
impact of maternal depression on maternal and child health, psychological wellbeing, and other possible consequences of chronic depression are important
aspects of mood to examine because of the prevalence of depression in the U.S.
Childbirth is a difficult process that can result in mental and physical
health issues. During pregnancy, typical hormone levels are askew leading to
mood instability (O’Hara, et al., 1990). Childbearing people are prescribed
medications to maintain and balance the hormonal levels. These hormonal
changes are often more severe in people with preexisting mental health disorders.
For example, childbearing people with clinically diagnosed bipolar disorder who
had a severe postpartum episode have a risk of greater than 60% for a severe
recurrence following a further pregnancy compared to a risk of around 25% for
bipolar people who have not experienced a postpartum episode (Robertson et al.
2005). Studies have shown that during late pregnancy childbearing people
experience significantly higher levels of depressive symptomatology and poor
social adjustment than non-childbearing people (O’Hara, et al., 1990). It is
important to examine more closely the effects of starting or stopping prescription
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medications while pregnant because of the vulnerability to depression and other
mood disorders that childbearing people have and the associated risks to the child
if the parent’s mental health is left untreated. Two interesting but detrimental
mood disorders that are often a result of these hormonal fluctuations are
postpartum depression and perinatal depression.
Postpartum depression is depression in the child-carrying person after they
have given birth. Studies have shown that postpartum depression is best treated
with antidepressants like selective serotonin reuptake inhibitors (SSRIs) such as
Venlafaxine (Cohen, et al., 2001). Although there have been many studies on the
effects of maternal postpartum depression on the child and how to treat
postpartum depression, there has been significantly less investigation of perinatal
depression.
Perinatal depression is when a major depressive disorder occurs before
pregnancy, during pregnancy, and up to a year after the child is born. Perinatal
depression effects 10–15% of childbearing people (Lee, et al., 2016). One of the
biggest concerns with perinatal depression is how to treat it and how the
depression and the treatment will affect the fetus and infant. Perinatal mood
disorders can manifest in the form of depression, anxiety, obsessive compulsive
disorder, post-traumatic stress disorder, bipolar disorder, and psychosis (Jones, et
al., 2010). One in seven childbearing people suffers from perinatal mood
disorders or anxiety symptoms making it more common than gestational diabetes
and gestational hypertension (Wood, 2020). Not only do these mood disorders
affect the pregnant person and fetus, but perinatal mood disorders also affect the
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infant’s health. Research has shown that perinatal mood disorders can lead to low
birth weight, preterm delivery, cognitive delays, and behavioral problems in the
child (Wood 2020).
To treat perinatal mood disorders, some patients will take antidepressants.
There has been discussion on the effects of maternal antidepressant use on
cognition and learning in children, and studies have found that there are no effects
of antidepressants on the child’s cognition (Nulman, et al., 2002). However, the
previous study only examined toddlers and did not assess older children or other
aspects of mental health. Although research has looked at the effects of perinatal
depression and perinatal usage of antidepressants on physical and cognitive
processes in infants, there is little research on the effects of perinatal
antidepressants on the psychological health of older children which is the focus of
this thesis (Deave, et al., 2008).
Previous research has shown that antidepressants taken during pregnancy
interact with the fetuses’ environment in the womb (Bellissima, et al., 2020).
Specifically, studies have shown that in patients that used antidepressants, there
was an increase in S100B protein levels in maternal-fetal biological fluids
(Bellissima, et al., 2020). S100B protein is involved in multiple cellular processes,
like cell differentiation, neurogenesis, neuronal plasticity, and can enhance
memory and overall cognition (Bellissima, et al., 2020). S100B can be a glia
marker protein because it may be released by astrocytes and oligodendrocytes.
S100B protein is an important protein in the brain and has even been used as an
early assessment to see if a patient has a traumatic brain injury (TBI). If there are
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higher levels of S100B protein that means there is a high level of cell death and in
turn a marker of a TBI (Thelin, Nelson, and Bellander, 2017).
The S100B protein was also shown to be an indicator of mood disorders.
S100B levels were increased in those with depression and were decreased using
antidepressant treatment (Schroeter, et al., 2013). Increased and disrupted S100B
protein levels have also been correlated with physical health issues in the fetus
and the parent like congenital heart disease and pre-eclampsia (Tskitishvili, et al.,
2006; Bokesch, et al., 2002).
There has been previous research investigating the effects of
antidepressant usage during pregnancy on the development of the offspring’s
brain. Specifically, one study found that in a rat model, fluoxetine treatment
during rat pregnancy decreased the anogenital distance (the distance from the
midpoint of the anus to the genitalia) in juvenile male offspring and in adult male
offspring it was found that there was a decrease in the number of intromissions
(insertion of penis into vagina), a longer latency to the first intromission, and a
longer latency to the first ejaculation (Rayen, et al., 2013). This same study also
found that exposure to fluoxetine and/or prenatal stress in the womb decreased the
sexually dimorphic nucleus of the preoptic area (SDN-POA) (Rayen, et al., 2013).
In addition, it was found that prenatal stress, but not exposure to developmental
fluoxetine, decreased the number of tyrosine hydroxylase (TH)-positive cells in
anteroventral periventricular nucleus (AVPv) and the volume of the posterior bed
nucleus of the stria terminalis (pBST) in male offspring (Rayen, et al., 2013).
This data shows that there is some kind if molecular level that antidepressant
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usage is affecting. Further research needs to look at what these changes can lead
to.
In comparison, other studies have shown that there is no correlation
between the use of antidepressants for perinatal depression and increased
pregnancy risks (Nordeng, et al., 2012). The current data do not suggest an
increased risk of malformations, preterm birth, or low birth weight following
prenatal exposure to antidepressants (Nordeng, et al., 2012). Previous research has
also shown that neither tricyclic antidepressants nor fluoxetine adversely affected
the child’s global IQ, language development, or behavior (Nulman, et al., 2002).
However, there was a significant and negative association between IQ and the
duration of the maternal depression (Nulman, et al., 2002). These data show that
there may be a correlation between the intensity and length of the depression and
the severity of the defects (mental and physical) on the offspring.
Prenatal depression is extremely important to treat because developmental
delays have been seen in children whose birth parent was depressed during
pregnancy (Deave, et al., 2008). However, the previous study did not include the
use of antidepressants during pregnancy to treat maternal depression. The
previous literature has examined the effects of antidepressant treatment for
maternal depression on a child’s cognition, learning ability (Deave, et al., 2008),
and IQ (Nulman, et al., 2002). There is a gap in the literature when it comes to the
investigation of the effects of the use of antidepressants during pregnancy on
mood related disorders like depression in an offspring later in childhood.
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The aim of this study was to investigate the influence of perinatal
antidepressant use on psychological development in children aged 9-14 years.
Specifically, the child’s mood with regards to mood disorders like depression,
anxiety, obsessive compulsive disorder, post-traumatic stress disorder, bipolar
disorder, and psychosis was examined. We hypothesize that the offspring of
childbearing people who took antidepressants during pregnancy will report more
negative mental health issues during adolescence compared to the offspring of
childbearing people who did not take antidepressants during pregnancy. Using
data from the national Adolescent Brain Cognitive Development (ABCD) Study
(abcdstudy.org), this thesis examined relationships between mood disorders in
children whose birth mother used perinatal antidepressants compared to the
children of a birth mother who was not treated with antidepressants during
pregnancy.
Methods
Previous data obtained by the Adolescent Brain Cognitive Development
(ABCD; abcdstudy.org) study were analyzed to test hypotheses about the
relationships between maternal antidepressant use and child mental health
measures. The ABCD study is a long-term study of brain development and child
health that is currently in progress at 21 sites throughout the U.S including the
University of Vermont. Children were included at the start of this study if they
met the following criteria: age 9.00 to 10.99 years at time of baseline assessments;
able to validly complete baseline assessments including MRI scanning; and fluent
in English.
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Children were excluded from the study for the following; MRI
contraindications such as orthodontic braces or irremovable dental appliances
containing ferromagnetic materials, claustrophobia that cannot be overcome with
repeated attempts, non-removable ferromagnetic metal implants that may distort
the images, or youth is pregnant on day of scanning based on urine pregnancy test
in postmenarcheal females; not fluent in English; non-correctable vision, hearing
or sensorimotor impairments that may confound the child's responses on the
assessments; a history of persistent major neurological disorders such as cerebral
palsy, brain tumor, stroke, brain aneurysm, brain hemorrhage, or subdural
hematoma (other exclusionary medical or neurological conditions included
multiple sclerosis, sickle cell disease, and the following seizure disorder
diagnoses: Lennox-Gastaut syndrome, Dravet syndrome, and Landau Kleffner
syndrome); gestational age less than 28 weeks and birthweight less than 1,200
grams (2 lb 10 oz). Birth complications that resulted in hospitalization for more
than a month are exclusionary (but not if the hospitalization was due to
prematurity alone); a current diagnosis of schizophrenia, autism spectrum disorder
(moderate or severe), mental retardation/intellectual disability, or
alcohol/substance use disorder. (A past diagnosis that has remitted is not
exclusionary); a history of traumatic brain injury (TBI): TBI with loss of
consciousness >30 minutes, or Amnesia >24 hours, or positive neuroimaging
findings (e.g., symptomatic hemorrhage) secondary to TBI; parent/guardian’s
report that the child would be unable to complete the baseline assessments (i.e.,
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answer questions, solve puzzles on an iPad, follow directions, and lie still in the
MRI scanner).
Parents were included if they were the primary custodial parent or legal
guardian with the child in the home for most of the year. Parents were excluded if
they were unwilling to attend annual visits and complete the parental assessments.
If a child and parent pair met all the criteria the children’s symptoms and
diagnoses and the biological parents’ prescription drug and street drug usage was
examined. There were 11,880 children who enrolled in the study as 9- or 10-yearolds. They are currently being followed for 10 years and are in approximately
year four of the study. Using the Kiddie Schedule for Affective Disorder and
Schizophrenia (KSADS; Kaufman et al. 2013)) the children’s diagnosis and
symptoms data were collected. The KSADS is a semi-structured interview used to
measure current and past symptoms of mood, anxiety, psychotic, and disruptive
behavior disorders in children ages 6-18 years old (Kaufman et al. 2013). A few
examples of questions asked were;
1. In the past two weeks, how often have you felt sad, down, or
depressed, with the down feeling lasting most of the day? (Townsend
et al., 2020).
The KSADS was updated to assess DSM-5 diagnoses, and it is this
version that has been translated into a computerized assessment which the ABCD
study uses (Kaufman et al. 2013). The data examined for this research question
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were the baseline or first symptom and diagnosis section of the KSADS and the 2
year follow up diagnosis and symptom section of the KSADS for the children.
The biological birth parent was asked whether they took a medication
before being pregnant with their child and if they answered “yes” they were asked
to list the prescription drugs they were taking. They were asked a similar question
again but this time they were asked whether they took prescription drugs while
they were pregnant. If they answered “yes” they were then asked to list the names
of those drugs. There was space for up to five different prescription drugs to be
listed. The subjects were also asked whether they had used alcohol, marijuana,
tobacco, heroin/morphine, or crack/cocaine while pregnant with their child.
Participants that left any of these questions blank (including the name of the
medication) were excluded from the analysis.
To begin, the data for the participants’ prescription drug usage had to be
sorted and categorized by the class of medication the subject was using before and
during pregnancy. The medications were broken up into five different groups: 1 antidepressants, 2 - opiates, 3 - stimulants, 4 - hormones, and 5 - other (including
bipolar medications and over the counter medications). The frequency of specific
prescription drug usage was obtained.
In addition to the parents’ data, the children’s data had to be organized
into the KSADS baseline symptom and diagnosis report and the 2-year follow up
report. The KSADS consisted of the child being interviewed every year in person
and completing a telephone interview at the 6-month intervals between the visits.
During these check-ins and visits, the children would answer multiple
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questionnaires about many domains of functioning and development including
mood and cognition. These data are then compiled into the symptoms and
diagnosis report which highlights different mood and cognition disorders like,
depression, bipolar, psychosis, schizophrenia, and suicidal ideation. The diagnosis
section was separated from the data and analyzed further.
Using the unique NDARs (numbers) that corresponded with each parent
and child pair, the children were matched up to the parents. Many of the parents
who left the ‘yes’ or ‘no’ answers blank or did not identify what type of
prescription drug was taken during pregnancy, were not included in the analysis
because it could not be confirmed whether there was the presence of a
prescription drug while in utero. Only biological parents were included in the
analysis. The children were sorted into different groups depending on what
prescription and over-the-counter drugs and street drugs the childbearing parent
took during pregnancy. There was also a group of children (n=8388) whose
biological mother did not take any prescription or street drugs while pregnant with
them. About 300 children were randomly selected from this group to be compared
with the other groups of children.
Using SPSS, independent samples T-tests were run between the children
in the perinatal antidepressant group and the children in the no perinatal
prescription or street drug group (control group). Independent samples T-tests
between the control group and each prescription drug class and all the street drugs
were analyzed as well. This same process was used for the 2-year follow up data.
The comparison data between medication and street drug usage to the children’s
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diagnosis report from the baseline and 2-year follow up were also analyzed to
examine any change over time using a one-way ANOVA.
Results
The total number of participants who took prescription drugs and or over
the counter medications while pregnant was 1525 (Table 1). Participants were
also surveyed on what types of street drugs they used while pregnant. Many
participants left the spaces blank while others answered ‘yes’ or ‘no’ to having
used the street drug while pregnant. Out of the total sample, 1250 participants
answered ‘yes’ to using one or more of the street drugs listed (Table 2.).
The one-way ANOVA between all the drug groups and the dependent
variables from the KSADS revealed that for the most part there was no effect of
maternal medication usage on a child’s mental health outcomes with two
important exceptions. There was an effect of maternal medication usage on
suicidal ideation (F(4,1797) =2.554, p=.04, Table 3.) Overall, two children out of
the 296 in the perinatal antidepressant group stated that they were experiencing
suicidal ideation. The other medication groups did not reveal any differences in
suicidal ideation. There was also an effect of medication group for present suicide
attempt, (F(4,1795) = 2.398, p=.048, Table 4.) Two children out of 296 in the
perinatal antidepressant group stated that they had a present suicide attempt. Other
reports of suicide attempts appear in one out of 135 of the perinatal opiates group
and one out of the ‘other’ perinatal medication group with 613 participants.
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In addition, we examined the change in KSADS mental health scores from
baseline to year two and found that there was an increase in mental health
diagnoses for every variable on the KSADS (smallest t (18302)=335.07, p<.001).
Discussion
We hypothesized that the offspring of childbearing people who took
antidepressants during pregnancy would report more negative mental health
issues in early adolescence compared to the offspring of childbearing people who
did not take antidepressants during pregnancy. The data showed that there was no
effect of maternal medication usage on the majority of the mental health measures
on the KSADS in children aged nine to 12 years old.
When the medication groups and mental health outcomes were analyzed
together, for the majority of the measures there was no effect of maternal perinatal
medication use on their children’s mental health with two important exceptions.
We did find an effect of medication group that was specific to the participants
who took antidepressants and their children’s mental health outcomes measured at
baseline in two of the measures on the KSADS. These variables were present
suicide attempts and suicidal ideation. This is an important finding however,
when we examined the number of suicide attempts at ages 9 and 10 there were
two children in the antidepressant group reported present suicide attempts. In
addition, there was one child in the opiate group and one child in the ‘other’ drug
group also reported present suicide attempts. There were no differences found
between these groups and the overall numbers endorsed in the sample were low.
In addition, two children in the antidepressant group were also found to have
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suicidal ideation. We examined these responses and found that they were from
four different children for the two significant suicide relevant variables. If a child
endorsed any suicide attempts and any reports of suicidal ideation the
investigators were automatically contacted and appropriate assessments,
interventions, and referrals were made. Regarding the current thesis study, there
were no higher reports of suicide attempts in the perinatal antidepressant group
compared to the other groups. It is important to recognize the seriousness of any
number of children reporting a suicide attempt or suicidal ideation, but these
reports are most likely not the result of the perinatal medication and may be a
result of external or confounding variables. This may consist of the child’s living
environment and even extend to what the mother was doing or eating while
pregnant.
There was also an attempt to examine the change in symptom and
diagnosis report over time across medication groups using a repeated measures
ANOVA and no significant effects were found for time or drug group. However,
the low number of reported suicides attempts likely explains this finding. Overall,
the hypothesis was not supported because there was no significant relationship
between diagnosis and perinatal medication usage.
From the baseline KSADS diagnosis and symptoms report to the two year
follow up there was an increase in diagnoses across the entire sample in every
variable. However, it is difficult to tell how many children were displaying a new
diagnosis compared to or in addition to existing mental health issues. This
increase in mental health symptoms may be due to the onset of puberty in the
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teenager participants. The onset of puberty typically occurs at age 8.0 to 14.9
years for females and from age 9.7 to 14.1 years for males (Lee, 1980). Onset of
puberty is usually considered to coincide with the last major step in brain
development which is the elimination of some 40% of neuronal synapses
(Saugstad, 1989). The ABCD study did examine the effects of puberty but those
data were not examined here. The onset of puberty brings an increase in
hormones thus leading to fluctuations in mood thus causing the onset of mood
disorders to begin around puberty (Saugstad, 1989).
Currently, doctors suggest terminating antidepressant usage while
pregnant and there is evidence that discontinuing or continuing antidepressant use
without dosage modification during pregnancy was associated with an increased
risk of depression during the remaining gestational period (Bérard et al., 2019).
Because of the gap in awareness and understanding that exists in the research area
and the public realm, many people who give birth still suffer from depression and
anxiety while pregnant which causes more severe and longer lasting changes in
the child (Rahman, et al., 2007). If the child-carrier experiences depression while
pregnant there is a greater chance their child will have a low birth weight
(Rahman, et al., 2007). Low birth weight is a significant issue in developing
countries and depression in the childbearing parent might be a valid screening
method for potential low birth weight in a child (Kiess, et al., 2009). Currently,
doctors and researchers have difficulty evaluating the evidence of whether
patients should take antidepressants during the perinatal period for mood
disorders because of the lack studies focusing on this issue.
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There are positives and negatives to taking antidepressants during
pregnancy. Untreated depression during pregnancy is a risk for the childbearing
parent and the child because there is an increase in the risk of intrauterine growth
restriction, low birth weight, and maternal-child relation disturbances
(Dubovicky, et al., 2017). Some research has shown that treating depression
during pregnancy and breastfeeding also represents a risk for the developing child
because SSRI/ SNRI antidepressants can cross the placenta, the blood-brain
barrier and pass into the milk, thus increasing the levels of monoamines in the
brain which influences development (Dubovicky, et al., 2017). However, perinatal
antidepressant usage did not have a significant effect on the child’s development.
The Dubovicky et al. findings show that perinatal antidepressant usage has no
effect on a child’s mental health at age 9 through 14. However, this study only
examined newborns and animal models opening the discussion for perinatal
antidepressant usage on adolescents.
Future research should examine differences between perinatal
antidepressant usage and untreated perinatal depression. One can examine
whether there is a difference in the child's mental health depending on whether the
perinatal depression was treated or not. Current studies have shown that untreated
depression can harm the child bearer, the fetus, and the newborn (Dubovicky, et
al., 2017). These same studies have shown that treated depression during
pregnancy and breastfeeding can also be a risk for the developing fetus and
neonate because of the increase in level of monoamines caused by the SSRI/
SNRI antidepressants crossing the placenta, the blood-brain barrier and passing
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into the milk (Dubovicky, et al., 2017). There are no studies weighing which is
the lesser of the two evils: treated or untreated perinatal depression. It is an issue
that pregnant people with mood disorders must consider for the health of their
unborn child. Decisions regarding perinatal antidepressant usage must be made
on a case-to-case basis.
In addition, studies examining depression and antidepressants during
pregnancy should also measure S100B protein levels in-utero for untreated
perinatal depression versus treated perinatal depression. Levels of S100B protein
in the children at ages 10-14 years should be examined as well. This will allow
researchers to investigate the lasting biological effects of perinatal antidepressant
usage at a molecular level. However, there is the chance that these levels may not
remain high for an entire decade. Examining S100B protein levels in infants may
be the first step in this research.
Future clinical research is needed to help provide physicians and their
patients with more accurate guidance on how to appropriately treat childbearing
people during pregnancy with mood disorders to protect the health of the parent
and child. By investigating mood in children whose birthing parent was
prescribed antidepressants during pregnancy compared to those who were not will
help determine if there are potential dangers to a child later in life. The goal is to
eventually increase the safety surrounding physical and mental health during
pregnancy for the childbearing person and their children.
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Tables:
Table 1. The total participants who have taken specified medication classes while
pregnant. The opiate and stimulant drug classes only include pregnant people who
took these medications as prescribed. Hormonal drugs include any kind of
hormones. The other category is made of any drug that does not full under the
other four categories which includes bipolar drugs. The reasons for taking these
drugs were not included.
Drug (prescribed/over the counter)

Total Users While Pregnant (n)

Antidepressant

304

Opiate

137

Stimulant

4

Hormonal

463

Other

617
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Table 2. The total participants that have taken one of the following street drugs
listed (not prescription drugs) while pregnant.
Drug (Prescribed/over the counter)

Total User While Pregnant (n)

Tobacco

620

Alcohol

315

Marijuana

245

Cocaine/Crack

51

Heroin/Morphine

19
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Table 3. Suicidal Ideation Active Intent Present. For the baseline assessment and
the medication class there was a significant relationship for suicidal ideation
active intent present (F(4,1797) = 2.554, p=.04.
Medication Class

Suicidal Ideation
Active Intent
Present (0 = no
or 1 = yes)

Frequency

Precent

Antidepressants

0

294

99.3

1

2

0.7

Total

296

100

Perinatal Antidepressant Usage and a Child’s Psychological Health 27

Table 4. Suicide Attempt Present. For the baseline assessment and the medication
class there was a significant relationship for suicide attempt present (F(4,1795) =
2.398, p=0.048). Any medication class not included had no reports of suicide
attempts.
Medication Class

Suicide Attempt
Present (0 = no
or 1 = yes)

Frequency

Precent

Antidepressants

0

294

99.3

1

2

0.7

Total

296

100

0

134

99.3

1

1

0.7

Total

135

100

0

612

99.8

1

1

0.2

Total

613

100

Opiates

Other
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Table 5. The total number of participants indicating symptoms present on the
KSADS during baseline and the 2 year follow up.
Diagnosis

Baseline

Year 2

(n)

(n)

Bipolar I Disorder, current episode manic

5

8

Bipolar I Disorder, current episode depressed

3

6

Bipolar I Disorder, currently hypomanic

2

1

Bipolar I Disorder, most recent past episode

49

157

8

19

Bipolar II Disorder, currently hypomanic

2

1

Bipolar II Disorder, currently depressed

1

4

Bipolar II Disorder, most recent past hypomanic

21

45

Unspecified Bipolar and Related Disorder,

10

22

Unspecified Bipolar and Related Disorder, PAST

111

127

Major Depressive Disorder Present

10

28

Major Depressive Disorder, Current, in Partial

2

20

Major Depressive Disorder, Past

54

163

Persistent Depressive Disorder (Dysthymia)

0

0

manic
Bipolar I Disorder, most recent past episode
depressed

current

Remission

PRESENT
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Persistent Depressive Disorder (Dysthymia) In

0

0

2

9

Unspecified Depressive Disorder Current

2

0

Unspecified Depressive Disorder PAST

49

158

Generalized Anxiety Disorder Present

7

36

Generalized Anxiety Disorder Past

6

53

Suicidal ideation Passive Present

23

54

Suicidal ideation Active method Present

8

29

Suicidal ideation Active intent Present

2

18

Suicidal ideation Active plan Present

7

11

Interrupted Attempt Present

0

3

Aborted Attempt Present

3

8

Suicide Attempt Present

3

7

Interrupted Attempt Past

2

3

Suicide Attempt Past

15

74

Partial Remission
Persistent Depressive Disorder (Dysthymia)
PAST

